Teva Pharmaceutical Industries Ltd., (NYSE and TASE:TEVA) today announced that ten company-sponsored abstracts will be presented at the 2016 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in San Francisco, California on November 10-14, 2016. Data for presentation include results from three Phase III studies and one Phase I study of fluticasone propionate/salmeterol (FS) RespiClick ®, a fixed-dose combination inhaled corticosteroid (ICS) and long-acting beta agonist (LABA) delivered via Teva's RespiClick ® breath-actuated, multi-dose dry powder inhaler (MDPI) and for fluticasone propionate (Fp) RespiClick ® an ICS monotherapy also delivered via the RespiClick ® device. This will be the first presentation of the Phase III clinical trial results for FS RespiClick ® and Fp RespiClick ®, which are currently under review with the U.S. Food & Drug Administration for the treatment of adolescent and adult patients with asthma. Abstracts of note include two poster presentations examining the efficacy and safety of Fp RespiClick ® and FS RespiClick ® at varying doses compared to placebo, and a poster presentation evaluating long-term safety of both products in asthmatic patients. In addition, a retrospective, observational study pertaining to Teva's rescue medication, ProAir ® HFA (albuterol sulfate) Inhalation Aerosol from its Health Economics & Outcomes Research division will be presented via oral presentation. The study evaluated the impact of rescue inhalers with integrated dose counters (IDC), specifically ProAir ® HFA, on healthcare utilization among asthmatic patients. Results from the study show how IDCs significantly contributed to improved outcomes for asthmatic patients while also reducing respiratory-related healthcare utilization, specifically hospitalizations and emergency department visits. "We look forward to presenting new data and analyses for a number of products in our growing respiratory portfolio at the ACAAI Annual Scientific Meeting as we continue our work to help address the needs of people living with respiratory disease," said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. "When it comes to asthma, there is not a one-size-fits-all approach for treatment. Whether enhancing delivery device technology, enabling patients to track remaining doses in an inhaler with an integrated dose counter, or developing targeted biologic therapies, Teva is committed to developing and delivering therapies that will help patients across the severity spectrum better manage their illness."